Squeezing the antibiotic balloon: The impact of antimicrobial classes on emerging resistance

Clinical Microbiology and Infection, Supplement

Volumn 11, Issue 5, 2005, Pages 4-16

  Peterson, Lancer R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antimicrobial agent use; Emerging resistance; Review

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CLAVULANIC ACID; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULPERAZON; SULTAMICILLIN; TAZOBACTAM; TIMENTIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG TARGETING; DRUG USE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

ACINETOBACTER; PSEUDOMONAS AERUGINOSA;

EID: 25144447426     PISSN: 14709465     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01238.x     Document Type: Review

References (99)

1. Drosten C, Günther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New Engl J Med 2003; 348: 1967-1976.
2. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
3. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36: 1268-1274.
4. Vandenesch F, Naimi T, Enright M et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9: 978-984.
5. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-1073.
6. McGeer A. News in antimicrobial resistance: documenting the progress of pathogens. Infect Control Hosp Epidemiol 2004; 25: 97-98.
7. Toubes E, Singh K, Yin D et al. Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? Clin Infect Dis 2003; 36: 724-730.
8. Masterton R, Drusano G, Paterson DL, Park G. Appropriate antimicrobial treatment in nosocomial infections - the clinical challenges. J Hosp Infect 2003; 55: 1-12.
9. Livermore DM. Bacterial resistance. Origins, epidemiology, and impact. Clin Infect Dis 2003; 36(suppl 1): S11-S23.
10. McGowan Jr JE, Tenover FC. Control of antimicrobial resistance in the healthcare system. Infect Dis Clin North Am 1997; 11: 297-310.
11. Saier MH Jr. Bacterial diversity and the evolution of differentiation. ASM News 2000; 66: 337-343.
12. Dutch Working Party on Antibiotic Policy. NETHMAP. 2004. [http://www.swab.nl].
13. Peterson LR, Dalhoff A. Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing? J Antimicrob Chemother 2004; 53: 902-905.
14. Burke JP. Antibiotic resistance - squeezing the balloon? JAMA 1998; 280: 1270-1271.
15. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96: 1152-1156.
16. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA 2003; 289: 885-888.
17. European Antimicrobial Resistance Surveillance System. EARSS interactive database access. 2004. [http://www.earss.rivm.nl/PAGINA/interwebsite/home_earss.html].
18. Livermore DM, Mushtaq S, James D et al. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalized patients in the British Isles. Int J Antimicrob Agents 2003; 22: 14-27.
19. Malik YA. Antimicrobial resistance update: cephalosporins and carbapenems. Singapore: Elsevier, 2003; 1-2.
20. Pharmaceutical Services Division of Malaysia. National drugs list. 2004. [http://www.pharmacy.gov.my/html/about_us_f.htm].
21. Thamprajamchit S, Chetchotisakd P, Thinkhamrop B. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. J Med Assoc Thai 1998; 81: 265-271.
22. Gerding DN, Peterson LR. Serum protein binding and extravascular distribution of antimicrobials. J Antimicrob Chemother 1985; 15: 136-138.
23. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851-1853.
24. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003; 16: 430-450.
25. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage. Ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35: 1284-1290.
26. Van Landuyt HW, Boelaert J, Glibert B, Gordts B, Verbruggen AM. Surveillance of aminoglycoside resistance. European data. Am J Med 1986; 80(suppl 6B): 76-81.
27. Gerding DN, Larson TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med 1985; 79(suppl 1A): 1-7.
28. Livermore DM. Bacterial resistance to carbapenems. Adv Exp Med Biol 1995; 390: 25-47.
29. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-1237.
30. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Invest Drugs 2002; 3: 218-224.
31. Corbella X, Montero A, Pujol M et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38: 4086-4095.
32. Lee S-O, Kim NJ, Choi S-H et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004; 48: 224-228.
33. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37: 214-220.
34. Kumarasinghe G, Chow C, Tambyah PA. Widespread resistance to new antimicrobials in a university hospital before clinical use. Int J Antimicrob Agents 2001; 18: 391-393.
35. Solomon S, Horan T, Andrus M et al. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003: Am J Infect Contro 2003; 31: 481-498.
36. Hocquet D, Bertrand X, Kohler T, Talon D, Plesiat P. Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother 2003; 47: 1887-1894.
37. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995; 79: 705-719.
38. Nordmann P. Trends in beta-lactam resistance among Enterobacteriaceae. Clin Infect Dis 1998; 27(suppl 1): S100-S106.
39. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-1089.
40. Eveillard M, Schmit JL, Eb F. Antimicrobial use prior to the acquisition of multiresistant bacteria. Infect Control Hosp Epidemiol 2002; 23: 155-158.
41. Landman D, Quale JM, Mayorga D et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY. Arch Intern Med 2002; 162: 1515-1520.
42. Peacock JE Jr, Marsik FJ, Wenzel RP. Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital. Ann Intern Med 1980; 93: 526-532.
43. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002; 8: 802-807.
44. Donskey CJ, Schreiber JR, Jacobs MR et al. A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. Clin Infect Dis 1999; 29: 573-579.
45. Tokars JI, Satake S, Rimland D et al. The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans' Affairs institution. Infect Control Hosp Epidemiol 1999; 20: 171-175.
46. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994; 89: 519-523.
47. Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001; 22: 572-575.
48. Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 2002; 35: 1457-1462.
49. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24: 699-706.
50. Fasola EL, Fasching CE, Peterson LR. Molecular correlation between in vitro and in vivo activity of β-lactam and β-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus (MRSA). J Lab Clin Med 1995; 125: 200-211.
51. Yokota T. Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin. APMIS 1989; 5(suppl): 9-16.
52. Finlay J, Miller L, Poupard JA. A review of the antimicrobial activity of clavulanate. J Antimicrob Chemother 2003; 52: 18-23.
53. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28: 1062-1066.
54. Hiramatsu K. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR 1997; 46: 624-626.
55. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118-124.
56. Peña C, Pujol M, Ardanuy C et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-58.
57. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-458.
58. Empey KM, Rapp RP, Evans ME. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 2002; 22: 81-87.
59. Lan CK, Hsueh PR, Wong WW et al. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. J Microbiol Immunol Infect 2003; 36: 182-186.
60. Flidel-Rimon O, Friedman S, Gradstein S, Bardenstein R, Shinwell ES. Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy. Acta Paediatr 2003; 92: 1205-1207.
61. Bantar C, Vesco E, Heft C et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimicrob Agents Chemother 2004; 48: 392-395.
62. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999; 43: 261-266.
63. Kolar M, Vagnerova I, Latal T et al. The occurrence of vancomycin-resistant enterococci in hematological patients in relation to antibiotic use. New Microbiol 2002; 25: 205-212.
64. Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12: 1217-1223.
65. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994; 89: 519-523.
66. Wilcox MH, Freeman J, Fawley W et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 54: 168-172.
67. Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003; 51(suppl 1): 29-35.
68. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32(suppl 1): S9-S15.
69. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64: 159-204.
70. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43: 287-291.
71. Oh H, Stenhoff J, Jalal S, Wretlind B. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Resist 2003; 9: 323-328.
72. Paramythiotou E, Lucet JC, Timsit JF et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38: 670-677.
73. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and oractice of infectious diseases, 4th edn. New York: Churchill Livingstone, 1995; 279-306.
74. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-686.
75. Karlowsky JA, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1672-1680.
76. Zervos MJ, Hershberger E, Nicolau DP et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37: 1643-1648.
77. Peterson LR, Postelnick M, Pozdol TL, Reisberg B, Noskin GA. Management of emerging fluoroquinolone resistance in Pseudomonas aeruginosa: outcome of monitored use in a referral medical center. Int J Antimicrob Agents 1998; 10: 207-214.
78. Paladino JA, Sunderlin JL, Forrest A, Schentag JJ. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003; 52: 457-463.
79. Beyer R, Pestova E, Millichap JJ, Noskin GA, Peterson LR. A convenient assay to estimate the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother 2000; 44: 798-801.
80. Pestova E, Millichap JJ, Siddiqui F, Noskin GA, Peterson LR. Evidence for the presence of non-PmrA multi-drug transport proteins in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 40: 553-556.
81. Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31: 1380-1385.
82. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 999-1005.
83. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-1422.
84. Bisognano C, Vaudaux PE, Lew DP, Ng EY, Hooper DC. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 1997; 41: 906-913.
85. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9: 730-733.
86. Gaynes R, Rimland D, Killum E et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38: 640-645.
87. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38: 646-648.
88. Nagarajan R. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother 1991; 35: 605-609.
89. Wilhelm MP, Estes L. Vancomycin. Mayo Clin Proc 1999; 74: 928-925.
90. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004; 23: 113-119.
91. Allington DR, Rivey MP. Quinupristin/dalfopristin: a therapeutic review. Clin Ther 2001; 23: 24-44.
92. Wester CW, Durairaj L, Evans AT, Schwartz DN, Husain S, Martinez E. Antibiotic resistance: a survey of physician perceptions. Arch Intern Med 2002; 162: 2210-2216.
93. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001; 29(suppl 2): 11-5.
94. Craig WA. Basic pharmacodynamics of antibacterials with clinical approaches to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.
95. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99.
96. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399-405.
97. Mathai D, Rhomberg PR, Biedenbach DJ, Jones RN, India Antimicrobial Resistance Study Group. India Antimicrobial Resistance Study Group. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis 2002; 44: 367-377.
98. Verma S, Joshi S, Chitnis V, Hemwani N, Chitnis D. Growing problem of methicillin resistant staphylococci - Indian scenario. Ind J Med Sci 2000; 54: 535-540.
99. Infectious Diseases Society of America. United States Public Health Service grading system for rating recommendations in clinical guidelines. Bethesda, MD: Infectious Diseases Society of America, 2004. http://www.idsociety.org/